High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique.

5.00
Hdl Handle:
http://hdl.handle.net/10541/92012
Title:
High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique.
Authors:
Khan, Parveen; McGown, Alan T; Dawson, Martin J; Jayson, Gordon C ( 0000-0002-8515-8944 ) ; Prendiville, Joseph A; Pettit, G R; Crowther, Derek
Abstract:
An HPLC assay incorporating a solid-phase extraction technique has been devised for bryostatin-1. Quantitation of bryostatin was found to be linear over the concentration range 0.012-25 microg/ml (0.2-25 ng on column) and was found to have a limit of detection of 0.2 ng on column, with a correlation coefficient of 0.9999. Following extraction of bryostatin over a range of concentrations from horse serum (0.012-25 microg/ml) and human serum (0.01-0.32 microg/ml) using a 100-mg C18 solid-phase extraction cartridge, extraction efficiencies consistently greater than 90% were obtained for extraction from horse serum and varied between 57 and 85% from human serum. However, on extending this work to blood samples from patients undergoing therapy with bryostatin-1, the drug was not detectable even at the maximum dose given, demonstrating the rapid loss of this agent from peripheral circulation.
Affiliation:
CRC Department of Experimental Chemotherapy, Paterson Institute for Cancer Research, Christie CRC Cancer Centre, Manchester, UK.
Citation:
High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. 1998, 709 (1):113-7 J. Chromatogr. B Biomed. Sci. Appl.
Journal:
Journal of Chromatography. B, Biomedical Sciences and Applications
Issue Date:
8-May-1998
URI:
http://hdl.handle.net/10541/92012
DOI:
10.1016/S0378-4347(98)00007-3
PubMed ID:
9653932
Type:
Article
Language:
en
ISSN:
1387-2273
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorKhan, Parveenen
dc.contributor.authorMcGown, Alan Ten
dc.contributor.authorDawson, Martin Jen
dc.contributor.authorJayson, Gordon Cen
dc.contributor.authorPrendiville, Joseph Aen
dc.contributor.authorPettit, G Ren
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-02-12T16:04:40Z-
dc.date.available2010-02-12T16:04:40Z-
dc.date.issued1998-05-08-
dc.identifier.citationHigh-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. 1998, 709 (1):113-7 J. Chromatogr. B Biomed. Sci. Appl.en
dc.identifier.issn1387-2273-
dc.identifier.pmid9653932-
dc.identifier.doi10.1016/S0378-4347(98)00007-3-
dc.identifier.urihttp://hdl.handle.net/10541/92012-
dc.description.abstractAn HPLC assay incorporating a solid-phase extraction technique has been devised for bryostatin-1. Quantitation of bryostatin was found to be linear over the concentration range 0.012-25 microg/ml (0.2-25 ng on column) and was found to have a limit of detection of 0.2 ng on column, with a correlation coefficient of 0.9999. Following extraction of bryostatin over a range of concentrations from horse serum (0.012-25 microg/ml) and human serum (0.01-0.32 microg/ml) using a 100-mg C18 solid-phase extraction cartridge, extraction efficiencies consistently greater than 90% were obtained for extraction from horse serum and varied between 57 and 85% from human serum. However, on extending this work to blood samples from patients undergoing therapy with bryostatin-1, the drug was not detectable even at the maximum dose given, demonstrating the rapid loss of this agent from peripheral circulation.en
dc.language.isoenen
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBryostatins-
dc.subject.meshChromatography, High Pressure Liquid-
dc.subject.meshHorses-
dc.subject.meshHumans-
dc.subject.meshLactones-
dc.subject.meshMacrolides-
dc.titleHigh-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Experimental Chemotherapy, Paterson Institute for Cancer Research, Christie CRC Cancer Centre, Manchester, UK.en
dc.identifier.journalJournal of Chromatography. B, Biomedical Sciences and Applicationsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.